top of page
Copy of MY MUST HAVE GLP-1 COMPANION! (1).png

on the pen doesn't exist without your

generosity

I'm Dave. On The Pen is my thing. My passion. But so are my 4 kids, and so is my day job. In order to sustain my efforts, I have to cover the costs involved with OTP. The website, the programs that make it pretty, and the tools that help people connect to it. A gift of ANY amount is greatly appreciated!

Untitled design (4).png

Lilly Releases Astonishing Reults of Latest Mounjaro Obesity Studies

Some astonishing results were released by Eli Lilly today on the study of Tirzepatide (the active poly-peptide in Mounjaro) in those with obesity. The results were as follows, or you can check out the video for the info as well!


The SURMOUNT-3 study looked at the effectiveness and safety of a drug called tirzepatide compared to a placebo (a dummy pill) over a 72-week period. Before the main study, participants went through a 12-week program involving a low-calorie diet, exercise, and counseling to help them lose weight.

Here are the key findings:

- At the end of the 12-week lead-in period, participants lost an average of 6.9% of their body weight.

- During the 72-week treatment period, tirzepatide was more effective than the placebo in two important ways:

1. People taking tirzepatide lost, on average, an additional 21.1% of their body weight compared to the placebo group.

2. 94.4% of those taking tirzepatide achieved an additional weight reduction of at least 5% from the starting point, while only 10.7% in the placebo group achieved the same.

In a secondary analysis:

- Participants who took tirzepatide lost an average of 26.6% of their body weight from the start of the study, after going through the 12-week lifestyle intervention and then taking tirzepatide for 72 weeks.

The full results of the study will be presented at a conference in October and later published in a scientific journal for other experts to review.



The SURMOUNT-4 study tested a drug called tirzepatide compared to a fake pill (placebo) for 52 weeks. Before that, all participants took tirzepatide for 36 weeks in an open-label period. The study had two parts: first, an open-label period where everyone took tirzepatide, and then a double-blind period where some continued on tirzepatide, while others switched to placebo.

Here are the key findings:

- During the open-label period of 36 weeks, participants lost an average of 21.1% of their body weight while on tirzepatide.

- In the double-blind period, tirzepatide was better than the placebo in helping people maintain weight loss.

- Those on tirzepatide, on average, lost an additional 6.7% of their body weight compared to those on placebo, who regained 14.8% of their weight at 88 weeks.

- Participants who stayed on tirzepatide throughout the study had a total average weight loss of 26.0% over the 88 weeks.


The full results of the study will be presented at a diabetes conference in October and later published in a scientific journal for experts to review.

261 views0 comments

Comments


bottom of page